References
- Jonsell R, Böttiger M. Vaccination mot mässling, påssjuka, röda hund [In Swedish]. Läkartidningen 1984; 81: 1632.
- Sedvall A, Romanus V, Edman G. Lägsta acceptabla nivå ej nådd för vaccinering mot mässling, påssjuka, röda hund [In Swedish]. Läkartidningen 1984; 81: 1633.
- Böttiger M, Christenson B, Romanus V, Taranger J, Strandell A. Swedish experience of a two-dose vaccination programme aiming at eliminating measles, mumps, and rubella. Br Med J 1987; 295: 1264–7.
- Romanus V. Vaccinationsstatistik från skolorna [In Swedish]. Elevvård och Hälsa 1996; 2: 22–5.
- Annual report of the Swedish Institute for Infectious Disease Control, 1995.
- Maldonado YA, Lawrence EC, DeHovitz R, Hartzell H, Albrecht P. Early loss of passive measles. Pediatrics 1995; 96: 447–50.
- Christenson B, Böttiger M. Measles antibody: Comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 1994; 12: 129–33.
- Böttiger M. Boosting effect of a second dose of measles vaccine given to 12-year-old children. Scand J Infect Dis 1993; 25: 239–43.
- Böttiger M. Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months. Vaccine 1995; 13: 1759–62.
- Broliden K, Abreu ER, Arneborn M, Böttiger M. Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose vaccination programme. Vaccine 1998; 16: 323–7.
- Böttiger M, Christenson B, Grillner L. Hepatitis A immunity in the Swedish population: a study of the prevalence of markers in the Swedish population. Scand J Infect Dis 1997; 29: 99–102.
- Christenson B, Böttiger M. Changes of immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule. Vaccine 1991; 9: 326–9.
- Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. Measles antibody: Re-evaluation of protective titers. J Infect Dis 1990; 162: 1036–42.
- WHO. Recommended childhood immunization schedule—United States 1995. MMWR 1995; 44: 1–9.
- WHO. Expanded programme on immunization-immunization schedules in the WHO European region 1995. WHO: Weekly Epidemiological Record 1995; 70: 221–7.
- Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose, vaccination program. N Engl J Med 1994; 331: 1397–402.
- Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine 1995; 13: 799–802.
- Krugman S. Further-attenuated measles vaccine: Characteristics and use. Rev Infect Dis 1983; 5: 477–81.
- Hutchins SS, Markowitz LE, Mead P, Mixon D, Sheline J, Greenberg N, Preblud SR, Orenstein WA, Hull HF. A school-based measles outbreak: The effect of a selective revaccination policy and risk factors of vaccine failure. Am J Epidemiol 1990; 132: 157–68.
- Markowitz LE, Preblud SR, Fine PEM, Orenstein WA. Duration of live measles-induced immunity. Pediatr Infect Dis J 1990; 9: 101–10.
- Matson DO, Byington C, Canfield M, Albrecht P, Feigin RD. Investigation of a measles outbreak in a fully vaccinated school population, including serum studies before and after revaccination. Pediatr Infect Dis J 1993; 12: 292–9.
- Ward BJ, Boulianne N, Ratnam S, Guiot MC, Couillard M, De Serres G. Cellular immunity in measles vaccine failure: Demonstration of measles antigen-specific lymphoproliferative responses, despite limited serum antibody production after revaccination. J Infect Dis 1995; 172: 1591–5.